683 Capital Management »

Kyverna Therapeutics shares owned by 683 Capital Management

Quarter-by-quarter ownership of Kyverna Therapeutics (KYTX) shares owned by 683 Capital Management from 13F filings

Historical chart of 683 Capital Management investment in Kyverna Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Kyverna Therapeutics held by 683 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Kyverna Therapeutics by 683 Capital Management

Quarter filed Position value Share count Share price at filing
2025-12-31 $1.1M 115k 9.40

More positions owned by 683 Capital Management

Palantir Technologies Cl A Put Option (PLTR)
Eli Lilly & Co. Put Option (LLY)
Capital One Financial (COF)
Tesla Motors Put Option (TSLA)
NVIDIA Corporation Put Option (NVDA)
Wave Life Sciences SHS (WVE)
Carvana Cl A (CVNA)
Madrigal Pharmaceuticals Put Option (MDGL)
Alnylam Pharmaceuticals (ALNY)
Praxis Precision Medicines I Com New Put Option (PRAX)
Bridgebio Pharma Note 2.500% 3/1 (Principal)
Protagonist Therapeutics (PTGX)
Gxo Logistics Incorporated Common Stock (GXO)
Hilton Grand Vacations (HGV)
Anaptysbio Inc Common (ANAB)

View all positions for 683 Capital Management

Top funds holding Kyverna Therapeutics

Vida Ventures Advisors
Gilead Sciences
Bain Capital Life Sciences Investors
Deerfield Management Company
Vanguard Group
AIGH Capital Management
Insight Holdings
Woodline Partners
Propel Bio Management
Mbb Public Markets I
Alyeska Investment Group
Millennium Management
BlackRock
RFG Advisory
Susquehanna International

View all funds holding Kyverna Therapeutics